Nagamine H. et al.

1/26

1	In	sulin-like Growth Factor 1 Receptor Expression Correlates
2		with Programmed Death Ligand 1 Expression and Poor
3		Survival in Non-small Cell Lung Cancer
4		
5	Hir	oaki Nagamine <sup>1,3</sup> ¶, Masakazu Yashiro <sup>2</sup> *¶, Megumi Mizutani <sup>3</sup> , Akira Sugimoto <sup>3</sup> ,
6	Yo	shiya Matsumoto <sup>3</sup> , Yoko Tani <sup>4</sup> , Kenji Sawa <sup>4</sup> , Hiroyasu Kaneda <sup>4</sup> , Kazuhiro Yamada <sup>3</sup> ,
7	Tet	suya Watanabe <sup>3</sup> , Kazuhisa Asai <sup>3</sup> , Satoshi Suzuki <sup>5&amp;</sup> , Tomoya Kawaguchi <sup>3,4</sup>
8		
9	1	Department of Respiratory Medicine, Osaka City University, Graduate School of
10		Medicine, Osaka, Japan
11	2	Molecular Oncology and Therapeutics, Osaka Metropolitan University, Graduate
12		School of Medicine, Osaka, Japan
13	3	Department of Respiratory Medicine, Osaka Metropolitan University, Graduate
14		School of Medicine, Osaka, Japan
15	4	Department of Clinical Oncology, Osaka Metropolitan University, Graduate School
16		of Medicine, Osaka, Japan
17	5	Department of Thoracic Surgery, Osaka Metropolitan University, Graduate School
18		of Medicine, Osaka, Japan

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice. 1

Nagamine H. et al.

2/26

1	9
1	/

- 20 \*Corresponding Author:
- 21 Masakazu Yashiro
- 22 ORCID: Masakazu Yashiro (https://orcid.org/0000-0001-5743-7228)
- 23 Email: <u>i21496f@omu.ac.jp</u> (MY)
- 24
- 25 <sup>¶</sup>These authors contributed equally to this work.
- &These authors also contributed equally to this work. 26
- 27
- 28 Short title: IGF1R is associated with PD-L1 expression and poor survival in
- NSCLC 29
- 30
- Keywords: IGF1R, lung cancer, NSCLC, OS, PD-L1, RFS 31

Nagamine H. et al.

3/26

#### Abstract 32

33	The insulin-like growth factor 1 receptor (IGF1R) has been associated with growth and
34	metastasis in various cancers. However, its role in postoperative recurrence and
35	prognosis in lung cancer lacks clear consensus. Therefore, this study aimed to
36	investigate the potential relationship between IGF1R and postoperative recurrence as
37	well as long-term survival in a large cohort. Additionally, we assessed the relationship
38	between IGF1R and programmed death ligand 1 (PD-L1) expression. Our study
39	encompassed 782 patients with non-small cell lung cancer (NSCLC). Immunostaining
40	of surgical specimens was performed to evaluate IGF1R and PD-L1 expression. Among
41	the patients, 279 (35.8%) showed positive IGF1R expression, with significantly worse
42	relapse-free survival (RFS) and overall survival (OS). Notably, no significant
43	differences in RFS and OS were observed between IGF1R-positive and -negative
44	groups in stages 2 and 3. However, in the early stages (0-1), the positive group
45	displayed significantly worse RFS and OS. In addition, PD-L1 expression was detected
46	in 100 (12.8%) patients, with a significant predominance in the IGF1R-positive. IGF1R
47	may serve as a prognostic indicator and a guide for perioperative treatment strategies in
48	early-stage lung cancer. In conclusion, our findings underscore an association between
49	IGF1R expression and poor survival and PD-L1 expression in NSCLC.

Nagamine H. et al.

4/26

#### Introduction 50

51	The insulin-like growth factor 1 receptor (IGF1R) is expressed in various
52	cancers [1-3] and is associated with cancer growth [4], metastasis [5, 6], and
53	malignancy [7, 8]. In lung cancer, particularly non-small cell lung cancer (NSCLC),
54	IGF1R expression is associated with carcinogenesis and proliferation [9, 10].
55	Nevertheless, the association between IGF1R expression and postoperative prognosis as
56	well as recurrence in lung cancer has been inconsistent [11-14], lacking a definitive
57	consensus.
58	In recent years, the expression of programmed death ligand 1 (PD-L1) has
59	attracted attention as a predictor of immune checkpoint inhibitor (ICI) efficacy in the
60	treatment of lung cancer [15]. Although the expression of IGF1R and PD-L1 has been
61	implicated in head and neck squamous cell carcinoma [16], their role in lung cancer
62	remains unknown. The development of lung cancers, particularly squamous cell
63	carcinoma (SCC), has been associated with smoking [17]. Moreover, smoking is known
64	to be involved in tumor-induced IGF1R expression [10]. However, it remains unclear
65	whether IGF1R expression is associated with smoking and PD-L1 expression in actual
66	clinical practice and whether it is involved in postoperative recurrence and survival in
67	lung cancer. Therefore, this study aimed to investigate the potential associations

Nagamine H. et al.

5/26

68	between IGF1R expression, PD-L1 expression, smoking history, postoperative
69	recurrence, and survival in lung cancer. To our knowledge, this is the first study to
70	comprehensively evaluate the relationship between IGF1R and these critical factors
71	using long-term observations on a large scale. We anticipate that our findings will
72	contribute to the ongoing efforts to optimize lung cancer management, leading to more
73	effective and personalized therapeutic interventions in the realm of precision medicine.

Nagamine H. et al.

6/26

#### Materials and methods 74

#### Patient and data collection 75

76 A total of 782 patients with NSCLC who underwent surgery at the Osaka

77 Metropolitan University Hospital between January 2010 and December 2019 were

included in this study. Cancer stage for all patients was assessed according to the Union 78

79 for International Cancer Control, 8th edition. Relapse-free survival (RFS) was

calculated from the date of surgery to the date of first recurrence or death from any 80

81 cause. Overall survival (OS) was calculated from the date of surgery to the date of death

82 from any cause. Our observations were conducted retrospectively, with August 31,

2023, as the data cutoff date, spanning a maximum of 10 years. At the cut-off date or 10 83

years after the start of observation, cases with no events were terminated from 84

85 observation. Between September 1, 2023, and October 31, 2023, we accessed medical

records for the collection of information, including personally identifiable details, 86

87 related to registered patients. This study was approved by the Osaka City university

- Ethics Committee (reference number 2019-006). Informed consent was obtained from 88
- 89 each patient. This study has been conducted according to the principles of the

90 declaration of Helsinki.

Immunohistochemistry 91

Nagamine H. et al.

7/26

92	Immunohistochemical staining was performed on paraffin-embedded sections
93	of primary surgically resected specimens obtained from patients with NSCLC. Slides
94	were deparaffinized using xylene and rehydrated with gradually decreasing
95	concentrations of ethyl alcohol. The slides were then incubated with methanol
96	containing 3% hydrogen peroxide at room temperature for 15 min to eliminate
97	endogenous peroxidase activity. Subsequently, the slides were heated in an autoclave at
98	105°C for 10 min in Target Retrieval Solution (Dako, Santa Clara, CA, USA).
99	Following this, the slides were blocked with 10% normal mouse serum for 10 min at
100	room temperature and incubated overnight at 4°C with the anti-IGF1R antibody
101	(NB110-87052, 1:200; Novus Biologicals LLC, Centennial, CO, USA). Subsequently,
102	the samples were incubated with a biotinylated secondary antibody for 10 min at room
103	temperature, followed by treatment with streptavidin-peroxidase reagent for 5 min at
104	room temperature, incubation in diaminobenzidine for 2 min at room temperature, and
105	counterstaining with 100% Mayer's hematoxylin for 40 s at room temperature. For PD-
106	L1 staining, sections were blocked with 10% normal rabbit serum, and an anti-PD-L1
107	antibody (ab205921, 1:150, Abcam, Cambridge, UK) was used as the primary antibody,
108	followed by reaction with diaminobenzidine for 7 min.

Statistical analysis 109

Nagamine H. et al.

8/26

110	The $\chi 2$ test was employed to evaluate the significance of differences in patient
111	characteristics between the IGF1R-positive and IGF1R-negative groups. Multiple
112	logistic regression analysis was utilized to analyze the relationship between IGF1R and
113	PD-L1 expression, incorporating factors age, sex, smoking history, Eastern Cooperative
114	Oncology Group Performance Status (ECOG PS), histology, pStage, pleural invasion,
115	lymphatic invasion, and vascular invasion. The Mann–Whitney U test was applied to
116	evaluate differences in smoking index or maximum tumor diameter between the IGF1R-
117	positive and negative groups. Survival curves were generated using Kaplan-Meier
118	method, and the log-rank test was used to compare cumulative survival durations in the
119	patient groups. In addition, the Cox proportional hazards model was used to compute
120	univariable and multivariable hazard ratios for the study parameters. Analyses were
121	performed using EZR in R Commander version 1.54 (Saitama Medical Center, Jichi
122	Medical University, Saitama, Japan). In all tests, $p < 0.05$ was considered to indicate
123	statistical significance.

Nagamine H. et al.

9/26

#### **Results** 124

#### Patient characteristics and the association of IGF1R expression with 125

smoking history and tumor size 126

127	A total of 782 patients were included in this study. Both IGF1R and PD-L1
128	were predominantly stained in the cytoplasm (Fig. 1A and 1B). IGF1R was identified as
129	positive in 279 patients (35.8%). The median age of the participants was 70.0 years
130	(range=33-91), with 497 (63.6%) patients being male. Five hundred twenty-one patients
131	had adenocarcinoma, 217 had SCC, 14 had adenosquamous cell carcinoma, 11 had
132	large cell carcinoma, nine had pleomorphic carcinoma, three had large cell
133	neuroendocrine carcinoma, two had adenocarcinoma in situ, one had mixed
134	adenocarcinoma and small cell carcinoma, one had SCC and small cell carcinoma, one
135	had NSCLC not otherwise specified, one had mucoepidermoid carcinoma, and one had
136	atypical adenomatous hyperplasia. The IGF1R-positive group exhibited significantly
137	higher proportions of patients who were $\geq 65$ years old, male, had a smoking history, a
138	performance status (PS) $\geq$ 1, had SCC, pStage $\geq$ 2, exhibited pleural invasion, had
139	vascular invasion, or showed PD-L1 expression (all p<0.01, p<0.01, p<0.01, p<0.01,
140	p<0.01, p<0.01, p=0.02, p<0.01, p<0.01, respectively) (Table 1). Multivariable analysis
141	revealed that PD-L1 expression is associated with IGF1R expression (Table 2). Both

Nagamine H. et al. 10/26

IGF1R-positive and PD-L1-positive group had a significantly higher smoking index 142

143 (p<0.01) (Fig. 2A and 2 B), and the IGF1R-positive group had a significantly larger

- 144maximum tumor diameter (p<0.01) (Fig. 2C).
- 145 Fig 1. Immunostaining for IGF1R and PD-L1.
- 146 (A) Immunostaining for IGF1R reveals predominant cytoplasmic staining. (B)
- 147 Immunostaining for PD-L1 reveals predominant cytoplasmic staining.
- 148 Table 1. Patient characteristics.

Nagamine H. et al.

11/26

	No. of all patients	IGF1R positive	IGF1R negative	p-value
	n=782	n=279 (35.8%)	n= 503 (64.2%)	p-value
Age				
<65	200 (25.6%)	50 (17.9%)	150 (29.8%)	<0.01
≥65	582 (74.4%)	229 (82.1%)	353 (70.2%)	
Sex				
Male	497 (63.6%)	210 (75.3%)	287 (57.1%)	<0.01
Female	285 (36.4%)	69 (24.7%)	216 (42.9%)	
Smoking history				
Current/Former	587 (75.1%)	243 (87.1%)	344 (68.4%)	<0.01
Never	195 (24.9%)	36 (12.9%)	159 (31.6%)	
ECOG PS				
0	573 (73.3%)	193 (68.8%)	380 (75.4%)	<0.01
1-3	115 (14.7%)	56 (20.2%)	59 (11.7%)	
Histology				
Sq	218 (27.9%)	137 (49.1%)	81 (16.1%)	<0.01
Non Sq	564 (72.1%)	142 (50.9%)	422 (83.9%)	
pStage				
0-1	494 (63.2%)	137 (49.1%)	357 (71.0%)	<0.01
2-3	288 (36.8%)	142 (50.9%)	146 (29.0%)	
Adjuvant therapy				
Done	192 (24.6%)	72 (25.8%)	120 (23.9%)	0.55
None	590 (75.4%)	207 (74.2%)	383 (76.1%)	

Pleural invasion

medRxiv preprint doi: https://doi.org/10.1101/2024.01.08.24300961; this version posted January 9, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license .					
	110		Nagamine H. <i>et al.</i>		
	Positive	228 (29.2%)	96 (34.4%)	132 (26.2%)	0.02
	Negative	548 (70.1%)	181 (64.9%)	367 (73.0%)	
Lymphatic inva	asion				
	Positive	212 (27.1%)	78 (28.0%)	134 (26.6%)	0.74
	Negative	566 (72.4%)	200 (71.7%)	366 (72.8%)	
Vascular invas	ion				
	Positive	169 (21.6%)	98 (35.1%)	71 (14.1%)	<0.01
	Negative	609 (77.9%)	180 (64.5%)	429 (85.3%)	
PD-L1					
	Positive	100 (12.8%)	68 (24.4%)	32 (6.4%)	<0.01
	Negative	682 (87.2%)	211 (75.6%)	471 (93.6%)	

## 149 IGF1R, insulin-like growth factor 1 receptor; ECOG PS, Eastern Cooperative Oncology

150 Group Performance Status; Sq, squamous cell carcinoma; PD-L1, programmed death

## 151 ligand 1.

### 152 Table 2. Multivariate analysis of the relationship between IGF1R expression and

## 153 **PD-L1 expression.**

Factor	Reference	OR (95%CI)	p-value
PD-L1	Negative	3.35 (1.95-5.73)	<0.01

154 IGF1R, insulin-like growth factor 1 receptor; OR, odds ratio; CI, confidence intervals;

155 PD-L1, programmed death ligand 1.

Nagamine H. et al.

13/26

#### 156 Fig 2. The association between IGF1R or PD-L1 and smoking index, as well as the

#### 157 correlation between IGF1R and tumor size.

- 158 (A) Comparison of smoking index between the IGF1R-positive and negative groups.
- 159 The IGF1R-positive group had a significantly larger smoking index. (B) Comparison of
- 160 smoking index between PD-L1-positive and negative groups. The PD-L1-positive group
- 161 had a significantly larger smoking index. (C) Comparison of maximum tumor diameter
- 162 between IGF1R-positive and negative groups. The IGF1R-positive group had a
- 163 significantly larger maximum tumor diameter.

#### **Relationship between IGF1R and relapse-free survival or overall** 164

survival 165

#### 166 In all patients, IGF1R positivity was associated with worse RFS (p<0.01) and

167 OS (p<0.01) (Fig. 3A and 3B). When evaluated by stage, IGF1R positivity was

- 168 associated with worse RFS (p<0.01) and OS (p<0.01) in Stage 0-1 (Fig. 4A and 4B).
- 169 However, no significant differences in RFS or OS were observed between IGF1R-
- 170 positive and negative patients in Stage 2 (p=0.60 and p=0.80, respectively) (Fig. 5A and
- 171 5B) or Stage 3 (p=0.89 and p=0.15, respectively) (Fig. 6A and 6B). In univariable
- 172 analysis of RFS in stage 0-1 patients, IGF1R positivity, male, smoking history, ECOG
- PS >1, pStage 2-3, pleural invasion, lymphatic invasion, and vascular invasion were all 173

Nagamine H. et al.

14/26

174	associated with significantly worse PFS (Table 3). In the multivariable analysis of RFS
175	in stage 0-1 patients, smoking history, ECOG PS≥1, lymphatic invasion, and vascular
176	invasion were associated with significantly worse PFS (Table 3). In univariable analysis
177	of OS in stage 0-1 patients, IGF1R positivity, male, smoking history, ECOG PS≥1, SCC
178	and vascular invasion were all associated with significantly worse OS (Table 4). In the
179	multivariable analysis of OS in stage 0-1 patients, ECOG PS≥1 was associated with
180	significantly worse OS (Table 4).
181	Fig 3. Kaplan-Meier curve depicting RFS and OS for all patients.
182	(A) Kaplan-Meier curve depicting RFS for all patients. The IGF1R-positive group
183	exhibited significantly worse RFS. (B) Kaplan-Meier curve depicting OS for all
184	patients. The IGF1R-positive group exhibited significantly worse OS.
185	Fig 4. Kaplan-Meier curve depicting RFS and OS in stage 0-1 patients.
186	(A) Kaplan-Meier curve depicting RFS in stage 0-1 patients. The IGF1R-positive group
187	exhibited significantly worse RFS. (B) Kaplan-Meier curve depicting OS in stage 0-1
188	patients. The IGF1R-positive group exhibited significantly worse OS.
189	Fig 5. Kaplan-Meier curve depicting RFS and OS in stage 2 patients.
190	(A) Kaplan-Meier curve depicting RFS in stage 2 patients. No significant difference was
191	observed between the IGF1R-positive and negative groups. (B) Kaplan-Meier curve for
	14

Nagamine H. et al.

15/26

#### 192 OS in stage 2 patients. No significant difference was observed between the IGF1R-

193 positive and negative groups.

#### 194 Fig 6. Kaplan-Meier curve depicting RFS and OS in stage 3 patients.

- 195 (A) Kaplan-Meier curve depicting RFS in stage 3 patients. No significant difference in
- 196 RFS was observed between the IGF1R-positive and negative groups. (B) Kaplan-Meier
- 197 curve depicting OS in stage 3 patients. No significant difference was observed between
- 198 the IGF1-positive and negative groups.

#### 199 Table 3. Multivariable analysis of RFS in stage 0-1 patients.

		RFS of stage 0-1 patients (n=494)					
Factor	Reference	Univariable analysis			Multivariable analysis		
		HR	95%CI	p-value	HR	95%CI	p-value
IGF1R	Negative	1.71	1.23-2.40	<0.01	1.29	0.85-1.96	0.23
Age	≤64	1.34	0.91-1.95	0.14			
Sex	Female	2.05	1.45-2.89	<0.01	1.35	0.87-2.11	0.18
Smoking history	Never	2.41	1.62-3.58	<0.01	1.75	1.04-2.95	0.04
ECOG PS	0	2.13	1.37-3.30	<0.01	2.05	1.30-3.23	< 0.01
Histology	NonSq	1.52	1.05-2.21	0.03	0.73	0.45-1.18	0.20
Adjuvant therapy	Done	0.66	0.66-1.68	0.84			
Pleural invasion	Negative	1.93	1.35-2.76	<0.01	1.32	0.87-2.04	0.19

medRxiv preprint doi: https://doi.org/10.1101/2024.01.08.24300961; this version posted January 9, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.							
			Nagam	ine H. <i>et al</i> .			16/26
Lymphatic invasion	Negative	2.26	1.57-3.25	< 0.01	1.70	1.10-2.63	0.02
Vascular invasion	Negative	2.68	1.80-3.98	< 0.01	1.91	1.17-3.12	< 0.01
PD-L1	Negative	1.49	0.90-2.47	0.12			

200 RFS, relapse-free survival; HR, hazard ratio; CI, confidence intervals; IGF1R, insulin-

201 like growth factor 1 receptor; ECOG PS, Eastern Cooperative Oncology Group

202 Performance Status; Sq, squamous cell carcinoma; PD-L1, programmed death ligand 1.

### 203 **Table 4. Multivariable analysis of OS in stage 0-1 patients.**

		OS of stage 0-1 patients (n=494)					
Factor	Reference	Univariable analysis			Multivariable analysis		
	-	HR	95%CI	p-value	HR	95%CI	p-value
IGF1R	Negative	1.98	1.35-2.91	<0.01	1.40	0.86-2.29	0.17
Age	≤64	1.26	0.81-1.94	0.31			
Sex	Female	2.79	1.82-4.29	< 0.01	1.69	0.99-2.91	0.06
Smoking history	Never	2.81	1.73-4.57	< 0.01	1.70	0.90-3.21	0.10
ECOG PS	0	2.61	1.60-4.28	< 0.01	2.24	1.34-3.73	< 0.01
Histology	NonSq	2.10	1.39-3.16	< 0.01	0.95	0.55-1.64	0.86
Adjuvant therapy	Done	1.14	0.65-1.99	0.65			
Pleural invasion	Negative	1.34	0.86-2.09	0.20			
Lymphatic invasion	Negative	1.39	0.86-2.23	0.18			
Vascular invasion	Negative	2.19	1.36-3.53	< 0.01	1.52	0.85-2.70	0.15

PD-L1 Negative	1.71	0.98-3.01	0.06
----------------	------	-----------	------

204 OS, overall survival; HR, hazard ratio; CI, confidence intervals; IGF1R, insulin-like

- 205 growth factor 1 receptor; ECOG PS, Eastern Cooperative Oncology Group Performance
- 206 Status; Sq, squamous cell carcinoma; PD-L1, programmed death ligand 1.

Nagamine H. et al.

18/26

#### Discussion 207

208	Although previous reports have not consistently linked IGF1R expression to
209	postoperative recurrence or prognosis in lung cancer [11-14], our large-scale, long-term
210	observational study demonstrates that IGF1R expression is associated with worse RFS
211	and OS, particularly in the early stages. In addition, in this study, IGF1R expression was
212	significantly correlated with PD-L1 expression, smoking history, and tumor size.
213	The IGF1R-positive group also showed significantly larger tumor sizes. IGF1R
214	is a factor associated with tumor growth [4], consistent with a relationship between
215	IGF1R expression and tumor size. In addition, IGF1R expression was associated with
216	shorter RFS and OS, particularly in early-stage lung cancer. Many treatment strategies
217	using ICI for neoadjuvant and adjuvant chemotherapy have been developed in recent
218	years [18, 19]. However, due to the favorable prognosis of early-stage lung cancer, it
219	was less amenable to the benefits of neoadjuvant and adjuvant chemotherapy. Based on
220	our study findings, IGF1R expression may serve as an informative marker for
221	determining appropriate perioperative chemotherapy for patients with early-stage lung
222	cancer. Furthermore, despite promising preclinical indications, IGF1R inhibitors have
223	not proven consistently effective in various types of cancer in clinical trials [20-22].
224	However, recent mouse experiments have revealed that reduced IGF1R expression

Nagamine H. et al.

19/26

225	enhances the effects of ICI [23], and that IGF1R expression correlates with the tumor
226	microenvironment [24], including immune cells. Combining IGF1R inhibitors with ICI
227	may hold promise for future therapies, especially as perioperative treatment for early-
228	stage lung cancer.
229	In this study, we observed a positive correlation between the expression of
230	IGF1R and PD-L1. Notably, in head and neck squamous cell carcinoma, where smoking
231	poses a risk [25], Interleukin-6 (IL-6) has been reported to upregulate IGF1R and PD-
232	L1 expression [16]. In the present study, the IGF1R-positive group had a significantly
233	higher smoking index, consistent with previous studies linking IGF1R expression to
234	smoking [14]. Smoking induces IL-6 expression in the lungs [26], potentially
235	contributing to the upregulation of both IGF1R and PD-L1 expression in lung cancer.
236	Additionally, the IGF1R-positive group had a significantly higher proportion of SCC,
237	widely known to be associated with smoking [17]. Smoking-induced inflammation also
238	enhances COX2 expression, which is associated with IGF1R expression in lung cancer
239	[10]. Various smoking-related mechanisms, such as IL-6 and COX-2, may elucidate the
240	association between IGF1R expression, smoking, SCC, and PD-L1 expression.
241	However, further research is needed to elucidate the mechanism of co-expression of
242	IGF1R and PD-L1. Our unpublished data indicate that OMUL-1, a human squamous

Nagamine H. et al.

20/26

243	lung cancer cell line, expresses high levels of both IGF1R and PD-L1. This cell line
244	may be useful for analyzing the mechanisms responsible for the co-expression of
245	IGF1R and PD-L1.
246	IGF1R expression was correlated with various factors, such as PD-L1, sex, and
247	age, which differed between the IGF1R-positive and negative groups. Additionally,
248	IGF1R expression was positively correlated with smoking index. Given the high
249	prevalence of male smokers in Japan [27], the prevalence of IGF1R-positive lung
250	cancer may be higher in males. Moreover, the smoking index tends to be higher in older
251	patients, and the population of nonsmokers has decreased in recent years [27], which
252	may explain the large number of older adults in the IGF1R-positive group.
253	One limitation of this study stems from its retrospective design. Further
254	research and prospective study are necessary to fully understand the clinical
255	implications of IGF1R expression.
256	In conclusion, our study reveals that higher IGF1R expression correlates with
257	poorer outcomes in terms of RFS and OS, particularly in patients with early-stage lung
258	cancer. Furthermore, our findings indicate a relationship between IGF1R expression in
259	lung cancer and several factors: PD-L1 expression, smoking history, and tumor size.

Nagamine H. et al.

21/26

#### Acknowledgment 260

- 261 We express our gratitude to Akiko Tsuda from the Molecular Oncology and
- 262Therapeutics department at Osaka Metropolitan University Graduate School of
- Medicine for her valuable technical assistance. 263

#### **Author contributions** 264

- Hiroaki Nagamine; conceptualization, data curation, formal analysis, investigation, 265
- 266 methodology, validation, visualization, writing original draft, writing review and editing
- 267 Masakazu Yashiro; conceptualization, data curation, formal analysis, investigation,
- 268 methodology, project administration, supervision, validation, visualization, writing
- 269 original draft, review and editing,
- Megumi Mizutani; data curation, formal analysis, investigation, validation, review and 270
- editing 271
- 272 Akira Sugimoto; data curation, formal analysis, investigation, validation, review and
- 273 editing
- 274Yoshiya Matsumoto; methodology, review and editing
- 275Yoko Tani; review and editing
- 276 Kenji Sawa; methodology, review and editing
- 277 Hiroyasu Kaneda; methodology, review and editing

Nagamine H. et al.

22/26

- 278 Kazuhiro Yamada; methodology, validation, supervision, review and editing
- 279 Tetsuya Watanabe; supervision, review and editing
- Kazuhisa Asai; supervision, review and editing 280
- 281 Satoshi Suzuki; data curation, formal analysis, investigation, validation, review and
- 282 editing
- 283 Tomoya Kawaguchi; review and editing

#### **Competing interests** 284

285 The authors declare no competing interests.

#### **Ethics declarations** 286

- 287 This study was approved by the Osaka City university Ethics Committee (reference
- 288 number 2019-006). Informed consent was obtained from the patient. This study has
- been conducted according to the principles of the declaration of Helsinki. 289

Nagamine H. et al.

23/26

#### References 290

291

292 1. Wu J, Yu E. Insulin-like growth factor receptor-1 (IGF-IR) as a target for prostate cancer 293 therapy. Cancer Metastasis Rev. 2014;33(2-3):607-17. doi: 10.1007/s10555-013-9482-0. 294 PubMed PMID: 24414227; PubMed Central PMCID: PMCPMC4096322.

295 2. Motallebnezhad M, Aghebati-Maleki L, Jadidi-Niaragh F, Nickho H, Samadi-Kafil H, 296 Shamsasenjan K, et al. The insulin-like growth factor-I receptor (IGF-IR) in breast cancer: biology 297 and treatment strategies. Tumour Biol. 2016;37(9):11711-21. Epub 20160721. doi: 298 10.1007/s13277-016-5176-x. PubMed PMID: 27444280.

299 Hu L, Xu X, Li Q, Chen X, Yuan X, Qiu S, et al. Caveolin-1 increases glycolysis in 3. 300 pancreatic cancer cells and triggers cachectic states. Faseb j. 2021;35(8):e21826. doi: 301 10.1096/fj.202100121RRR. PubMed PMID: 34320244.

302 Heidegger I, Kern J, Ofer P, Klocker H, Massoner P. Oncogenic functions of IGF1R and 4. 303 INSR in prostate cancer include enhanced tumor growth, cell migration and angiogenesis. 304 Oncotarget. 2014;5(9):2723-35. doi: 10.18632/oncotarget.1884. PubMed PMID: 24809298; 305 PubMed Central PMCID: PMCPMC4058040.

306 5. Xu XL, Guo AX, Pan QY, Chang AL, Zhao CR. MiR-99a suppresses cell migration and 307 invasion by regulating IGF1R in gastric cancer. Eur Rev Med Pharmacol Sci. 2019;23(17):7375-308 82. doi: 10.26355/eurrev 201909 18845. PubMed PMID: 31539124.

309 Alfaro-Arnedo E, López IP, Piñeiro-Hermida S, Canalejo M, Gotera C, Sola JJ, et al. 6. 310 IGF1R acts as a cancer-promoting factor in the tumor microenvironment facilitating lung 311 metastasis implantation and progression. Oncogene. 2022;41(28):3625-39. Epub 20220610. doi: 312 10.1038/s41388-022-02376-w. PubMed PMID: 35688943; PubMed Central PMCID: 313 PMCPMC9184253.

314 7. Joehlin-Price AS, Stephens JA, Zhang J, Backes FJ, Cohn DE, Suarez AA. Endometrial 315 Cancer Insulin-Like Growth Factor 1 Receptor (IGF1R) Expression Increases with Body Mass 316 Index and Is Associated with Pathologic Extent and Prognosis. Cancer Epidemiol Biomarkers Prev. 317 2016;25(3):438-45. Epub 20151218. doi: 10.1158/1055-9965.Epi-15-1145. PubMed PMID: 318 26682991; PubMed Central PMCID: PMCPMC5075967.

319 Du P, Liu F, Liu Y, Shao M, Li X, Qin G. Linc00210 enhances the malignancy of thyroid 8. 320 cancer cells by modulating miR-195-5p/IGF1R/Akt axis. J Cell Physiol. 2020;235(2):1001-12. 321 Epub 20190625. doi: 10.1002/jcp.29016. PubMed PMID: 31240707.

322 Xu X, Qiu Y, Chen S, Wang S, Yang R, Liu B, et al. Different Roles of the Insulin-like 9. 323 Growth Factor (IGF) Axis in Non-small Cell Lung Cancer. Curr Pharm Des. 2022;28(25):2052-

Nagamine H. et al.

24/26

324 64. doi: 10.2174/1381612828666220608122934. PubMed PMID: 36062855.

325 10. Põld M, Krysan K, Põld A, Dohadwala M, Heuze-Vourc'h N, Mao JT, et al. 326 Cyclooxygenase-2 modulates the insulin-like growth factor axis in non-small-cell lung cancer. 327 Cancer Res. 2004;64(18):6549-55. doi: 10.1158/0008-5472.Can-04-1225. PubMed PMID: 328 15374967.

329 11. Dziadziuszko R, Merrick DT, Witta SE, Mendoza AD, Szostakiewicz B, Szymanowska 330 A, et al. Insulin-like growth factor receptor 1 (IGF1R) gene copy number is associated with survival 331 in operable non-small-cell lung cancer: a comparison between IGF1R fluorescent in situ 332 hybridization, protein expression, and mRNA expression. J Clin Oncol. 2010;28(13):2174-80. 333 Epub 20100329. doi: 10.1200/jco.2009.24.6611. PubMed PMID: 20351332; PubMed Central 334 PMCID: PMCPMC2860435.

335 12. Gately K, Forde L, Cuffe S, Cummins R, Kay EW, Feuerhake F, et al. High coexpression 336 of both EGFR and IGF1R correlates with poor patient prognosis in resected non-small-cell lung 337 cancer. Clin Lung Cancer. 2014;15(1):58-66. Epub 20131107. doi: 10.1016/j.cllc.2013.08.005. 338 PubMed PMID: 24210543.

339 13. Nakagawa M, Uramoto H, Oka S, Chikaishi Y, Iwanami T, Shimokawa H, et al. Clinical significance of IGF1R expression in non-small-cell lung cancer. Clin Lung Cancer. 340 341 2012;13(2):136-42. Epub 20111201. doi: 10.1016/j.cllc.2011.10.006. PubMed PMID: 22133293. 342 14. Zhao S, Qiu Z, He J, Li L, Li W. Insulin-like growth factor receptor 1 (IGF1R) expression 343 and survival in non-small cell lung cancer patients: a meta-analysis. Int J Clin Exp Pathol. 344 2014;7(10):6694-704. Epub 20140915. PubMed PMID: 25400749; PubMed Central PMCID: 345 PMCPMC4230063.

346 Yu H, Boyle TA, Zhou C, Rimm DL, Hirsch FR. PD-L1 Expression in Lung Cancer. J 15. 347 Thorac Oncol. 2016;11(7):964-75. Epub 20160423. doi: 10.1016/j.jtho.2016.04.014. PubMed 348 PMID: 27117833; PubMed Central PMCID: PMCPMC5353357.

349 16. Li J, Xiao Y, Yu H, Jin X, Fan S, Liu W. Mutual connected IL-6, EGFR and LIN28/Let7-350 related mechanisms modulate PD-L1 and IGF upregulation in HNSCC using immunotherapy. Front Oncol. 2023;13:1140133. Epub 20230412. doi: 10.3389/fonc.2023.1140133. PubMed 351 352 PMID: 37124491; PubMed Central PMCID: PMCPMC10130400.

353 17. Wang X, Wang T, Hua J, Cai M, Qian Z, Wang C, et al. Histological types of lung cancer 354 attributable to fine particulate, smoking, and genetic susceptibility. Sci Total Environ. 355 2023;858(Pt 2):159890. Epub 20221102. doi: 10.1016/j.scitotenv.2022.159890. PubMed PMID: 356 36334679.

357 Forde PM, Spicer J, Lu S, Provencio M, Mitsudomi T, Awad MM, et al. Neoadjuvant 18. 358 Nivolumab plus Chemotherapy in Resectable Lung Cancer. N Engl J Med. 2022;386(21):1973-85. 359 Epub 20220411. doi: 10.1056/NEJMoa2202170. PubMed PMID: 35403841; PubMed Central

Nagamine H. et al.

25/26

360 PMCID: PMCPMC9844511.

361 19. Felip E, Altorki N, Zhou C, Csőszi T, Vynnychenko I, Goloborodko O, et al. Adjuvant 362 atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer randomised, 363 а multicentre, (IMpower010): open-label, phase 3 trial. Lancet. 364 2021;398(10308):1344-57. Epub 20210920. doi: 10.1016/s0140-6736(21)02098-5. PubMed 365 PMID: 34555333.

366 20. Qu X, Wu Z, Dong W, Zhang T, Wang L, Pang Z, et al. Update of IGF-1 receptor 367 inhibitor (ganitumab, dalotuzumab, cixutumumab, teprotumumab and figitumumab) effects on 368 cancer therapy. Oncotarget. 2017;8(17):29501-18. doi: 10.18632/oncotarget.15704. PubMed 369 PMID: 28427155; PubMed Central PMCID: PMCPMC5438747.

370 21. Chiappori AA, Otterson GA, Dowlati A, Traynor AM, Horn L, Owonikoko TK, et al. A 371 Randomized Phase II Study of Linsitinib (OSI-906) Versus Topotecan in Patients With Relapsed 372 Cancer. Oncologist. 2016;21(10):1163-4. Epub 20160930. Small-Cell Lung doi: 10.1634/theoncologist.2016-0220. PubMed PMID: 27694157; PubMed Central PMCID: 373 374 PMCPMC5061534.

375 22. Fassnacht M, Berruti A, Baudin E, Demeure MJ, Gilbert J, Haak H, et al. Linsitinib (OSI-376 906) versus placebo for patients with locally advanced or metastatic adrenocortical carcinoma: a 377 double-blind, randomised, phase 3 study. Lancet Oncol. 2015;16(4):426-35. Epub 20150318. doi: 378 10.1016/s1470-2045(15)70081-1. PubMed PMID: 25795408.

379 23. Ajona D, Ortiz-Espinosa S, Lozano T, Exposito F, Calvo A, Valencia K, et al. Short-term 380 starvation reduces IGF-1 levels to sensitize lung tumors to PD-1 immune checkpoint blockade. 381 Nat Cancer. 2020;1(1):75-85. Epub 20200113. doi: 10.1038/s43018-019-0007-9. PubMed 382 PMID: 35121837.

383 24. Galifi CA, Wood TL. Insulin-like growth factor-1 receptor crosstalk with integrins, 384 cadherins, and the tumor microenvironment: sticking points in understanding IGF1R function in 385 cancer. Endocr Relat Cancer. 2023;30(10). Epub 20230825. doi: 10.1530/erc-23-0031. PubMed 386 PMID: 37490874.

387 25. Hayes RB, Ahn J, Fan X, Peters BA, Ma Y, Yang L, et al. Association of Oral Microbiome 388 With Risk for Incident Head and Neck Squamous Cell Cancer. JAMA Oncol. 2018;4(3):358-65. 389 doi: 10.1001/jamaoncol.2017.4777. PubMed PMID: 29327043; PubMed Central PMCID: 390 PMCPMC5885828.

391 Francus T, Romano PM, Manzo G, Fonacier L, Arango N, Szabo P. IL-1, IL-6, and 26. 392 PDGF mRNA expression in alveolar cells following stimulation with a tobacco-derived antigen. 393 Cell Immunol. 1992;145(1):156-74. doi: 10.1016/0008-8749(92)90320-o. PubMed PMID: 394 1423641.


395 27. Tanaka H, Mackenbach JP, Kobayashi Y. Widening Socioeconomic Inequalities in


Nagamine H. et al.

26/26

396 Smoking in Japan, 2001-2016. J Epidemiol. 2021;31(6):369-77. Epub 20201125. doi:
397 10.2188/jea.JE20200025. PubMed PMID: 32595181; PubMed Central PMCID:
398 PMCPMC8126678.

## Figure 1. Nagamine H. et al.





## Figure 2. Nagamine H. et al.




Figure 3. Nagamine H. et al.




Figure 4. Nagamine H. et al.




Figure 5. Nagamine H. et al.




Figure 6. Nagamine H. et al.

